170 related articles for article (PubMed ID: 2968399)
1. Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action.
Rosenthal GJ; Weigand GW; Germolec DR; Blank JA; Luster MI
J Immunol; 1988 Jul; 141(2):410-6. PubMed ID: 2968399
[TBL] [Abstract][Full Text] [Related]
2. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?
Fairbanks LD; Rückemann K; Qiu Y; Hawrylowicz CM; Richards DF; Swaminathan R; Kirschbaum B; Simmonds HA
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):143-52. PubMed ID: 10432311
[TBL] [Abstract][Full Text] [Related]
4. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
5. Effect of lactoferrin on the methotrexate-induced suppression of the cellular and humoral immune response in mice.
Artym J; Zimecki M; Kruzel ML
Anticancer Res; 2004; 24(6):3831-6. PubMed ID: 15736418
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects on the immune system of methotrexate and trimetrexate.
Rosenthal GJ; Germolec DR; Lamm KR; Ackermann MF; Luster MI
Int J Immunopharmacol; 1987; 9(7):793-801. PubMed ID: 2962953
[TBL] [Abstract][Full Text] [Related]
7. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)].
Nakamura T; Ueda T; Uchida M
Gan To Kagaku Ryoho; 1992 Mar; 19(3):409-20. PubMed ID: 1543370
[TBL] [Abstract][Full Text] [Related]
8. Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells.
Rodenhuis S; McGuire JJ; Sawicki WL; Bertino JR
Leukemia; 1987 Feb; 1(2):116-20. PubMed ID: 2959824
[TBL] [Abstract][Full Text] [Related]
9. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists.
Ohnoshi T; Ohnuma T; Takahashi I; Scanlon K; Kamen BA; Holland JF
Cancer Res; 1982 May; 42(5):1655-60. PubMed ID: 6978176
[TBL] [Abstract][Full Text] [Related]
10. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate.
Allegra CJ; Hoang K; Yeh GC; Drake JC; Baram J
J Biol Chem; 1987 Oct; 262(28):13520-6. PubMed ID: 2443493
[TBL] [Abstract][Full Text] [Related]
11. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of the induction of the differentiation of HL-60 leukemia cells by antifolates.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Commun; 1989; 1(3):199-207. PubMed ID: 2700913
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.
Genestier L; Paillot R; Fournel S; Ferraro C; Miossec P; Revillard JP
J Clin Invest; 1998 Jul; 102(2):322-8. PubMed ID: 9664073
[TBL] [Abstract][Full Text] [Related]
14. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
[TBL] [Abstract][Full Text] [Related]
15. The effect of 1,25-dihydroxyvitamin D3 on in vitro immunoglobulin production in human B cells.
Iho S; Takahashi T; Kura F; Sugiyama H; Hoshino T
J Immunol; 1986 Jun; 136(12):4427-31. PubMed ID: 3519769
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry.
Taylor IW; Tattersall MH
Cancer Res; 1981 Apr; 41(4):1549-58. PubMed ID: 6163527
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid.
Lorico A; Toffoli G; Boiocchi M; Erba E; Broggini M; Rappa G; D'Incalci M
Cancer Res; 1988 Apr; 48(8):2036-41. PubMed ID: 3349474
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of methotrexate, two nonclassic folic acid antagonists, and cytarabine on hematopoietic precursor cells.
Marsh JC
Cancer Treat Rep; 1982 Mar; 66(3):499-504. PubMed ID: 6460555
[TBL] [Abstract][Full Text] [Related]
19. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
